Business Wire

Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand

Share

Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/

David Manlowe, CEO of Benefit Street Partners

The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019 and 2022, respectively – and reflects increasing investor demand for a specialist global credit platform with expertise across the full spectrum of the asset class. A refreshed logo and new website domain accompany the brand alignment, and from this week Alcentra branded funds start to take on the BSP name.1 Overall, Franklin Templeton’s alternative credit platform – which also includes direct lender Apera – is on track to exceed $100 billion in AUM in 2026.

According to new research also published today by BSP, which surveyed 135 global institutional investors with a combined AUM of $8 trillion,2 around 93% of global institutional investors intend to either maintain (42%) or increase (51%) their exposure to alternative credit in 2026. The main motivation is the pursuit of greater diversification (85%) and the potential for higher total returns in alternatives than traditional fixed income (81%). As investors grow and diversify their alternative credit allocations, 81% consider a specialist asset class focus the key to delivering strong performance.

Over the next 12 months, 47% of respondents intend to increase their exposure to infrastructure debt, making it the most popular strategy, followed by direct lending (39%), asset-based lending (35%), special situations and distressed debt (30%), commercial real estate debt (28%) and CLOs (16%).

To meet this strong and varied demand, BSP is targeting a mix of organic and inorganic growth over the next five years, with the possibility for further acquisitions where attractive opportunities complement its existing offering. This includes expansion into new markets in Asia and the Middle East, and into adjacencies within the full alternative credit landscape.

David Manlowe, CEO of Benefit Street Partners, said: “BSP and Alcentra are complementary pioneers in alternative credit with long track records of successfully supporting investors through multiple market cycles. So this alignment under a unified brand is a natural next step for our combined global platform, which has become increasingly integrated in recent years and already shares world-class research, distribution, as well as operational teams and infrastructure.

“Critically, this move ensures we are optimally positioned to meet our clients’ evolving alternative credit needs, including exposure to new asset classes and geographies around the world, leveraging our global platform and institutional capabilities to support the full scope of our investors’ ambitions.”

While Franklin Templeton is integrating its expanding alternative credit platform, it remains committed to offering clearly differentiated investment capabilities to its investors within that global platform, particularly in certain local markets and where there is a specific area of focus. This was demonstrated by the recent addition of Apera Asset Management in October 2025, focused on lower-middle-market direct lending across Europe.

With Apera now forming part of BSP, the combined business is today responsible for $78 billion AUM in corporate credit strategies and $14 billion in commercial real estate debt strategies.3

Allison Davi, Senior Managing Director, Co-COO and Head of Business Development at BSP, added: “The message from our clients is clear: they want access to the best investment opportunities available across the expanding alternative credit landscape, but managed by a single, trusted and global partner. That means providing a multijurisdictional yet integrated platform, which brings together decades of alternative credit experience, long-standing relationships, and on-the-ground expertise to help investors achieve their goals.”

1 BSP’s new website is: http://bspcredit.com/. A high-resolution version of the new logo is available on request.
2 The survey was conducted on behalf of Benefit Street Partners by CoreData Research in November and December 2025 and focused on institutional investors in Australia, Bahrain, Canada, China, Denmark, Finland, France, Germany, Italy, Israel, Japan, Norway, Qatar, Saudi Arabia, South Korea, Sweden, United Arab Emirates (UAE), United Kingdom and the United States.
3 Estimate as of 12/31/25.

Disclaimer

This communication may contain forward-looking statements, which reflect current expectations, estimates, and projections about future events or performance. These statements are based on assumptions and are subject to risks, uncertainties, and other factors—many of which are beyond our control—that could cause actual results to differ materially from those expressed or implied. Words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “project,” and similar expressions are intended to identify such statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

About Benefit Street Partners

Benefit Street Partners (BSP) is an alternative credit pioneer with $92 billion1 in assets under management (including Apera). It seeks to deliver attractive, risk-adjusted returns through its deep specialism, long-term relationships and global reach. A wholly owned subsidiary of Franklin Templeton, BSP is focused exclusively on credit. Through its disciplined, solutions-oriented approach, BSP unlocks opportunities across market cycles and geographies. The firm manages strategies spanning private debt, real estate debt, structured credit, and liquid loans. For more information, visit http://bspcredit.com/.

1 Estimate as of 12/31/25.

About Franklin Templeton

Franklin Templeton is a trusted investment partner, delivering tailored solutions that align with clients’ strategic goals. With deep portfolio management expertise across public and private markets, we combine investment excellence with cutting-edge technology. Since our founding in 1947, we have empowered clients through strategic partnership, forward-looking insights, and continuous innovation – providing the tools and resources to navigate change and capture opportunity.

To learn more, visit franklintempleton.com and follow us on LinkedIn.
Franklin Resources, Inc. [NYSE: BEN]

View source version on businesswire.com: https://www.businesswire.com/news/home/20260123270080/en/

Contacts

Media contacts
Sam Turvey
Global Head of Communications, BSP
s.turvey@bspcredit.com
+44 (0) 782 783 6246

Anthony Cornwell
Lansons
BenefitStreetPartners@lansons.com
+44 (0) 792 973 0785

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 11:15:00 EET | Press release

IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition. “Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significan

Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release

Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline

Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 09:00:00 EET | Press release

Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Head CP Sourcing at Syngenta. "This tailored approach allows us to make meaningful progress toward our carbon reduction targets for Syngenta AG while m

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 09:00:00 EET | Press release

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a

Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN ® in Pediatric Spasticity26.1.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye